Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ERN1 | O75460 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31057535 | 1.00 | MAOB (0.46) | MAOBERN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL2317333 | 0.86 | ALDH1A1 (0.43) | MAOBERN1ALDH1A1NFE2L2 | |
| SCHEMBL610877 | 0.83 | ALDH1A1 (0.48) | MAOBERN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL95708 | 0.83 | ERN1 (0.50) | ERN1ALDH1A1KMT2ATDP1MEN1 | |
| SCHEMBL3059913 | 0.78 | MAOB (0.34) | MAOB | |
| SCHEMBL29057998 | 0.78 | MAOB (0.38) | MAOBERN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL29947357 | 0.77 | MAOB (0.42) | MAOBKMT2ATDP1NFE2L2IKBKB | |
| SCHEMBL22579195 | 0.77 | MAOB (0.42) | MAOBALDH1A1KMT2ATDP1NFE2L2 | |
| SCHEMBL1986111 | 0.77 | MAOB (0.42) | MAOBKMT2ATDP1NFE2L2IKBKB | |
| SCHEMBL3272039 | 0.77 | ERN1 (0.35) | MAOBERN1ALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262596-A1 | METHODS OF MAKING OSIVELOTOR | PFIZER INC. (US) | 2025-12-26 | — | — | WO | claimed |
| CN-116425716-A | Preparation method of epinastine intermediate | 南京艾德凯腾生物医药有限责任公司 | 2023-07-14 | — | — | CN | claimed |
| CN-110818679-B | Synthetic method of 4-bromobenzo [ b ] thiophene | 苏州诚和医药化学有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-111004211-B | Synthetic method of brexpiprazole intermediate 4-bromobenzo [ b ] thiophene | 苏州诚和医药化学有限公司 | 2021-04-02 | — | — | CN | claimed |
| CN-111004211-A | Synthetic method of brexpiprazole intermediate 4-bromobenzo [ b ] thiophene | 苏州诚和医药化学有限公司 | 2020-04-14 | — | — | CN | claimed |
| CN-110818679-A | Synthetic method of 4-bromobenzo [ b ] thiophene | 苏州诚和医药化学有限公司 | 2020-02-21 | — | — | CN | claimed |
| CN-108440388-B | The preparation method of one kind (S) -4- ((the bromo- 6- fluorophenyl of 2-) hydroxymethyl) piperidines -1- t-butyl formate | 上海再启生物技术有限公司 | 2019-06-11 | — | — | CN | claimed |
| CN-108440388-A | The preparation method of one kind (S) -4- ((the bromo- 6- fluorophenyls of 2-) hydroxymethyl) piperidines -1- t-butyl formates | 上海再启生物技术有限公司 | 2018-08-24 | — | — | CN | claimed |
| CN-102070420-B | Method for preparing 2-bromo-6-fluorobenzaldehyde | UNIV CHANGZHOU | 2013-12-18 | — | — | CN | claimed |
| CN-103113202-A | (2E, 5E)-2, 5-benzal cyclopentanone analogue and preparation method and application thereof | UNIV MUDANJIANG MEDICAL | 2013-05-22 | — | — | CN | claimed |
| CN-103044224-A | Penta-1,4-diene-3-ketone analogue and preparation method and application thereof | UNIV MUDANJIANG MEDICAL | 2013-04-17 | — | — | CN | claimed |
| CN-103044322-A | (3E, 5E)-3,5-bipiperidyl-4-ketone analogue and preparation method and application thereof | UNIV MUDANJIANG MEDICAL | 2013-04-17 | — | — | CN | claimed |
| CN-103044227-A | (2E, 6E)-2,6-bis(benzylidene)cyclohexanone analogue and preparation method and application thereof | UNIV MUDANJIANG MEDICAL | 2013-04-17 | — | — | CN | claimed |
| CN-102070420-A | Method for preparing 2-bromo-6-fluorobenzaldehyde | UNIV CHANGZHOU | 2011-05-25 | — | — | CN | claimed |
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12577239-B2 | Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds | PI INDUSTRIES LTD. (IN) | 2026-03-17 | — | — | US | disclosed |
| EP-1153909-A2 | Ortho-substituted benzaldehydes, process for their preparation, and their use | Clariant GmbH (DE) | 2001-11-14 | — | — | EP | disclosed |
| WO-2001068653-A1 | DIHYDROIMIDAZO[2,1-B]THIAZOLE AND DIHYDRO-5H-THIAZOLO[3,2-A]PYRIMIDINES AS ANTIDEPRESSANT AGENTS | KNOLL GMBH (DE) | 2001-09-20 | — | — | WO | disclosed |
| CN-1231661-A | Lactams and imides of aralkyl and arylalkylene heterocycles | PFIZER (US) | 1999-10-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | MAOB 4825/4885ERN1 1739/4885ALDH1A1 3268/4885 |
| US-12577239-B2 | Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds | SULT1E1, CBR1, SULT1A1 | MAOB 778/4885ERN1 1731/4885ALDH1A1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.